Immutep Limited (IMMP) Stock
IMMP Key Statistics
About Immutep Limited
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftilagimod alpha (efti or IMP321), a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer. The company also develops TACTI-002, which is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer; TACTI-003 that is in Phase IIb clinical trial to treat HNSCC; and INSIGHT-004 and INSIGHT-003, which is in a Phase I clinical trial for the treatment of solid tumors, as well as INSIGHT-005 that is in Phase I/IIa clinical trial to treat solid tumors. Its other products include IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. Immutep Limited has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
CEO: Marc Voigt. Company website
IMMP — Frequently Asked Questions
What is the IMMP stock price today?
Immutep Limited (IMMP) trades at $4.69, up 1,679.89% on the day, as of Nov 12, 2026 10:46 UTC.
What is Immutep Limited's market cap?
Immutep Limited has a market capitalisation of $691.17M, calculated from the live IMMP share price and shares outstanding.
What is the P/E ratio of IMMP?
IMMP has no meaningful price-to-earnings ratio: Immutep Limited lost $0.57 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Immutep Limited make?
Immutep Limited generated revenue of $7.92M over the trailing twelve months, which puts the stock at 87.24 times sales.
What is the 52-week range for IMMP?
IMMP has traded between $4.67 and $55.60 over the past 52 weeks, and the last price is 91.6% below that high.
Is Immutep Limited profitable?
No. Immutep Limited is loss-making, with a net margin of -1,404.13% over the trailing twelve months.
What is the analyst price target for IMMP?
Wall Street analysts rate IMMP Buy, with an average price target of $4.25, 9.4% below the current price.
What sector is Immutep Limited in?
Immutep Limited is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in AU .
Who is the CEO of Immutep Limited?
Marc Voigt is the chief executive of Immutep Limited, which employs 41 people.
Where can I track IMMP in real time?
QFI Terminal shows IMMP with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See IMMP live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open IMMP in Terminal See plans